Document is current

Article History

Received: 23 January 2023

Accepted: 8 April 2023

First Online: 21 April 2023

Declarations

:

: The IRB (Comité de Protection des Personnes Sud-Est II) approved the REALISM study (ref. 2015–42-2), and this study was registered at clinicaltrials.gov (NCT 02638779). The CIC approved the MIPrea study (IRB #5044). Informed consent was obtained from participants or their family members. The research was carried out in accordance with the Declaration of Helsinki.

: Not applicable.

: MB, MC, AF, MAC, EC, EP, KBP and JFL are bioMérieux’s employees. JFL and GM are co-inventors in patent applications covering the previous markers. bioFire—a bioMérieux company—holds patents on the technology. This does not alter the authors’ adherence to all the policies on sharing data and materials.